Cheif of Advisory Board- Marco Matucci Cerinic MD, PhD, FRCP, FBSRhon, University of Florence, Florence, Italy

Marco Matucci-Cerinic is Professor of Rheumatology and Medicine at the Department of Musculoskeletal Medicine , and Director of the Rheumatology Department AVC and of the Division of Rheumatology AOUC, at the Azienda Ospedaliera Universitaria Careggi in Florence, Italy.

Dr Matucci-Cerinic is professor of Rheumatology at the University of Florence, Italy. He has published more than 600 peer review manuscripts widely in the field of rheumatology, particularly on the pathogenesis, clinical features and treatment of scleroderma, on spondyloarthritis and on osteoarthtritis. He has also served on various international and national committees. Dr Matucci-Cerinic has served as EULAR General Secretary and as Chairman of the EULAR Scleroderma Trial and Research Group (EUSTAR). He is currently chairman of the World Scleroderma Foundation and Editor in Chief of the Journal of Scleroderma & Related Diseases. He is also Associate Editor of Arthritis Research & Therapy and Clinical & Experimental Rheumatology, past Associate Editor and Co-Editor of Rheumatology. He serves on the boards of Annals of the Rheumatic Diseases, Rheumatology, Journal of Rheumatology, Scandinavian Journal of Rheumatology and other rheumatology journals.

 

Yanick Allanore , MD , Paris Descartes University, Paris, France

Prof. Allanore is Professor of Rheumatology in Paris Descartes University with a broad background in autoimmune diseases and systemic sclerosis (SSc) in particular.
Prof. Allanore reasearch includes clinical aspects of SSc with particular interest in the cardiovascular complications and biomarkers. In addition, Prof. Allanore is the head of a research team at Cochin Institute working on immunogenetics in SSc.
He is involved in several international bodies and networks and hashave been elected in 2016 as the Chairman of the European network working on SSc (EUSTAR).

 

Christopher Denton, PhD FRCP, Royal Free Hospital and UCL Division of Medicine, London, UK

Professor Denton studied medicine at Guy’s Hospital in London and obtained a PhD from University College London and trained in connective tissue diseases in London. Following a Wellcome Trust Advanced Fellowship in molecular genetics at the M.D. Anderson Cancer Center in Houston, USA, he was an Arthritis Research UK Senior Clinical Research Fellow 2000-2010. He has published extensively on laboratory and clinical aspects of connective tissue disease and pulmonary hypertension.

He leads a large clinical programme in scleroderma at the Royal Free Hospital and co-ordinates multidisciplinary care for more than 1400 patients. He was previously chair of the Heberden Scientific Committee of the British Society for Rheumatology (BSR) and currently chairs the UK Scleroderma Study Group (UKSSG).

 

Oliver Distler, MD, University Hospital Zurich, Zurich, Switzerland

Oliver Distler, MD, is Professor of Rheumatology and Director of the Department of Rheumatology at the University of Zurich, Switzerland. His main research interests in systemic sclerosis are the molecular mechanisms leading to microvascular lesions, the biological action of pro-fibrotic mediators, validation of biomarkers, and design of proof-of-concept trials as well as phase III trials. Professor Distler is an editorial board member of several rheumatology journals and Treasurer of EUSTAR.

 

Daniel Eric Furst, MD, University of California, Los Angeles, USA

Daniel E. Furst is Professor of Medicine at the University of California(emeritus), Los Angeles (UCLA), Medical Center, David Geffen School of Medicine, Department of Medicine, Division of Rheumatology. He is also Adjunct professor at the university of Washington, Seattle Washington and Research Professor at the University of Florence, Florence, Italy.
He has part time practices at the Arthritis Associates of Southern California and the Seattle Rhuematology Associates in Seattle Washington.

Dr. Furst received his MD from Johns Hopkins University, where he also completed his internship and residency. He completed two fellowships, one in Rheumatology at UCLA Medical Center, and a second in clinical pharmacology at the University of California, San Francisco Medical Center.

 

Dinesh Khanna, MD , University of Michigan, Michigan, USA

Prof. Khanna is a Professor of Medicine and Director of the University of Michigan (UM) Scleroderma Program. UM Scleroderma Program is a tertiary referral center for patients with scleroderma and related conditions. The program sees approximately 1,200-1,500 unique patient visits on an annual basis and has 3 full-time faculty members and 5 coordinators. Prof. Khanna have expertise in developing/validating outcome measures for clinical trials and led the development of the Combined Response Index in Systemic Sclerosis (NIH/NIAMS funded effort), which is now included as primary, secondary, and exploratory measures in ongoing trials. Dr. Khanna’s research has focused on the development of outcome measures and refinement of trial design in scleroderma. Based on his expertise in trial design and outcome measures, he co-led the EULAR Points to Consider recommendations for trial design in SSc and will chair a project with the NIH and FDA colleagues to develop a white paper for clinical trials in SSc.

 

Thomas Krieg, MD, University of Cologne, Cologne, Germany

Professor Thomas Krieg is Director and Chairman in the Department of Dermatology at the University of Cologne, in addition to being the Dean of the Medical Faculty at the University of Cologne. He has extensive experience in the field of dermatology, as well as serving for several years as Director of the Center for Molecular Medicine in Cologne. He is a Fellow of the Royal College of Physicians, London, and was awarded honorary membership of the Polish and Hungarian Dermatological Societies. Professor Krieg has an extensive publication record and has co-written many papers on systemic sclerosis and wound healing, particularly with regards to the molecular mechanisms involved in pathogenesis.